DermWire | Newest Articles Newest Articles en-us Fri, 20 Apr 2018 01:07:51 GMT Fri, 20 Apr 2018 01:07:51 GMT DermWire Marriage May Reduce Risk of Dying from Melanoma Married folks are more likely to spot a melanoma early, compared with individuals who were never married, divorced or widowed, a new study shows. Researchers tracked data from more than 52,000 people in the United States who were diagnosed with a melanoma from 2010 through 2014. Married patients were more likely to be diagnosed with early stage melanoma than those who were never married, divorced or widowed, the study found. While almost half of married patients presented with a very treatabl… Thu, 19 Apr 2018 04:00:00 GMT Physician Assistant Groups Respond to JAMA Dermatology Study: "Fundamentally Flawed" The American Academy of PAs (AAPA) and the Society of Dermatology PAs (SDPA) have issued a statement criticizing an article published in JAMA Dermatology as fundamentally flawed with too small a sample size to be representative of the PA profession. The statement is available here. Thu, 19 Apr 2018 04:00:00 GMT Saudi Arabia Welcomes Scalisi Skin Care Select doctors’ offices and medical clinics across Saudi Arabia now carry the Scalisi collection. This adds to their existing distribution in spas and medispas in the US, Wynn and Encore Resorts in both Las Vegas, and Macau, China, and online on,, and "We are thrilled and honored to be partnering with StarCare Medical, Inc. based out of Jeddah, Saudi Arabia, who are now selling our line throughout their network of doctors’ offices and c… Thu, 19 Apr 2018 04:00:00 GMT Study: Derms More Likely than PAs to Catch Early Skin Cancer Physician assistants may be more likely than dermatologists to perform unnecessary skin biopsies to check for cancer and are less likely to accurately diagnose early stage skin cancers, according to new research conducted by the University of Pittsburgh School of Medicine (UPMC). The study examined the medical records of 33,647 skin cancer screening examinations in 20,270 unique patients who underwent screening at UPMC-affiliated dermatology offices from 2011 through 2015. The research team … Wed, 18 Apr 2018 04:00:00 GMT Most Indoor Tanners Aren’t Getting Screened for Skin Cancer Most indoor tanners are not getting checked for skin cancer, a new study shows. Researchers analyzed data from the National Health Interview Survey of more than 30,000 U.S. adults. They looked at rates of skin cancer screening by a physician among people who had indoor tanned and those who had not. About 16.5 percent of the sample had indoor tanned, most of them more than a year ago. About 19.5 percent of non-indoor tanners had been screened for skin cancer, and a little more than 30 perce… Wed, 18 Apr 2018 04:00:00 GMT Cutera: 20 Years, 20 Products Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20th anniversary of the company, Cutera announces the global launch of the enlighten SR, a new picosecond platform specifically designed for skin revitalization and the treatment of benign pigmented lesions. With more than 20 pro… Wed, 18 Apr 2018 04:00:00 GMT It's Official: Dyve Biosciences Has Launched Dyve Biosciences has officially launched, and is focused on its core Dyve Technology, an innovative approach that enables therapy to be transported quickly and deeply through the skin, allowing rapid penetration into targeted tissue. This unique approach offers the promise of delivering therapeutic molecules to areas that could previously only be reached with a needle, Dyve suggests. Dyve Biosciences' first product, Dyve Comfort (the next generation of what was previously Procicept), is a… Wed, 18 Apr 2018 04:00:00 GMT Dermatologist Publishes Practice Planning Guide, "Moxie Mindset" New York City dermatologist Dina D. Strachan, MD has published "Moxie Mindset," a book that offers "secrets of building a profitable, independent physicians practice in a competitive environment." Dr. Strachan details her personal journey to building a thriving practice in the competitive New York market and shares the lessons she learned along the way. In addition to her personal insights, she shares the inspiration she received from expert business coaches. She tackles … Wed, 18 Apr 2018 04:00:00 GMT News You Can Use: Simple One-Page Tool Improves Patient Satisfaction with Doctor Visit A simple, one-page form given to patients ahead of time can significantly improve satisfaction with care, according to a study by Duke Health researchers. The low-tech tool, which asks for a list of the topics patients wants to discuss during their visit, helps patients focus on what’s important to them. It also asks if all their questions were addressed at the end of the visit and if they were satisfied, giving doctors real-time feedback on how well they’re addressing their patie… Tue, 17 Apr 2018 04:00:00 GMT Using Anti-PD-1 Therapy Pre-Surgery in Melanoma Patients Can Identify Those Most Likely to Benefit Shifting use of anti-PD-1 drugs to before surgery may provide clues about which patients will benefit and which may be at increased risk for recurrence, according to new research out of the Abramson Cancer Center of the University of Pennsylvania. The data is slated to be presented in a symposium at the American Association for Cancer Research Annual Meeting in Chicago. “Building on our previous research that shows the effect of anti-PD-1 therapy can be seen in patients’ blood … Mon, 16 Apr 2018 04:00:00 GMT Tattoo Removal Misperceptions Abound More than four in five adults with (86 percent) and without (82 percent) tattoos have misconceptions about tattoo removal, including confusion regarding side effects, cost and removability, according to a new Merz survey. In addition to not knowing how the process works, many underestimate how long it takes. On average adults with tattoos believe removal takes five treatment sessions. In reality, it takes an average of seven to 10 sessions to fully remove a tattoo. These misconceptions are li… Thu, 12 Apr 2018 04:00:00 GMT RealSelf Names Tanja Omeze Chief Marketing Officer Ms. Tanja Omeze is RealSelf’s first ever chief marketing officer (CMO). As CMO, Ms. Omeze leads global marketing to increase awareness, engagement and connections among and between consumers and medical aesthetic professionals. Ms. Omeze recently served as head of marketing for the Amazon Video store and previously held a variety of marketing leadership roles at Weight Watchers, Scholastic and Verizon Wireless. Her prior experience also includes consulting on digital strategies in th… Thu, 12 Apr 2018 04:00:00 GMT Maryland Gets SUNucated And then there were nine. Governor Larry Hogan signed HB 427 into law, making Maryland the second state this year and the ninth one overall to ensure state policy allows students to possess and use sunscreen at school. The legislation is based on the American Society for Dermatologic Surgery Association’s (ASDSA) model legislation known as SUNucate to eliminate barriers that prohibit students from possessing and using over-the-counter sunscreen in school. Sunscreen often falls unde… Wed, 11 Apr 2018 04:00:00 GMT New JAMA Dermatology Publication Features AID Accelerator Fund to Enable Progress of Promising Early-stage Scientific Technologies A new article, "Catalyzing Future Drug, Device, and Information Technology Breakthroughs in Dermatology", in JAMA Dermatology features the Advancing Innovation in Dermatology (AID) Accelerator Fund. AID has created this mechanism to help enable and speed the product development of important scientific discoveries and new early-stage technologies with the potential to significantly improve skin health. The fund will facilitate collaborative partnerships by engaging individuals, includin… Wed, 11 Apr 2018 04:00:00 GMT Ortho Dermatologics’ DUOBRII Improves Psoriasis Symptoms As Early As Two Weeks DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion demonstrated significant superiority over vehicle as early as two weeks, according to new research in Journal of the American Academy of Dermatology. DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion is an investigational topical treatment for plaque psoriasis. If approved, DUOBRII will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulati… Mon, 9 Apr 2018 04:00:00 GMT Take That, Kim and Kylie : Most Millennials Don't Want Your Advice on Cosmetic Surgery When it comes to deciding on nips and tucks, millennials are not inclined to trust social media or celebs, a new ZALEA survey suggests. Instead, three-quarters of this hot-to-trot demographic are more apt to listen to family/friends and physicians as a source of information on cosmetic surgery. Nearly 50 percent trusted Google search results. But when it came to social media, the group started to throw some shade. More than 50 percent said they don’t trust social media and surprisingly,… Fri, 6 Apr 2018 04:00:00 GMT FDA Approves Sonoma Pharmaceuticals' Antimicrobial Post-Therapy Gel Sonoma Pharmaceuticals, Inc. has received a new 510(k) clearance from the FDA for an antimicrobial post-therapy gel. Under the supervision of a healthcare professional, the new product is intended for the management of post-non-ablative laser therapy procedures and post-microdermabrasion therapy as well for use following superficial chemical peels. It may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns. Dr. Michael Gold, founder of Gol… Fri, 6 Apr 2018 04:00:00 GMT Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canada Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename Eskata. Neal Walker, CEO of Aclaris commented, “This agreement marks an important milestone for Aclaris as our first entry into the international dermatology market. Cipher has a strong presen… Fri, 6 Apr 2018 04:00:00 GMT Coming Soon to a City Near You: Sciton Inc.’s Bright Lights Big City BBL 2018 Tour Sciton. Inc.’s Bright Lights Big City BroadBand Light (BBL) 2018 Tour is now in its third year. The 2018 Tour, featuring San Francisco dermatologist Patrick Bitter Jr., MD, kicks off in early June in Fort Lauderdale, followed by Chicago, New York City and Austin, before making a last stop in Washington D.C. in November. Dr. Bitter Jr. created the FotoFacial® treatment, a key procedure using intense pulsed light (IPL) to rid the skin of vascular lesions, pigmentation problems, acn… Thu, 5 Apr 2018 04:00:00 GMT GlobalData: Sun Pharma’s Ilumya To Face Strong Competition in the US market It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from GlobalData, a leading data and analytics company.

 In March 2018 the US Food and Drug Administration (FDA) approved Sun Pharma’s Ilumya for the treatment of adults with moderate-to-severe plaque psoriasis (PsO), who are candidates for systemic therapy or phototherapy. Ilumya is the second interleukin-23 (IL-23) inhibitor to gain FDA approval within the past year, following the… Wed, 4 Apr 2018 04:00:00 GMT BTL to Showcase Groundbreaking Research, Latest Innovation at American Society for Laser Medicine Surgery Annual Conference BTL has had nine scientific abstracts and four ePosters accepted for presentation at the 38th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS) taking place April 11-15. This unprecedented number of accepted papers for the brand, further solidifies its leadership position and continued growth within the aesthetics and women's health categories. The brand will be introducing an entirely new category of technology and revolutionary body sculpting treatment… Tue, 3 Apr 2018 04:00:00 GMT DefenAge® Skincare Trio Performs Well in New Study Progenitor Biologics’ DefenAge® Skincare, a-three-step system “globally improves the visual appearance of aging skin without irritation, dryness, or inflammation,” according to new research in the Journal of Drugs in Dermatology (JDD). The participant- and investigator -blinded, placebo-controlled, multi-center trial was performed in outpatient settings on forty-four female subjects, 41-71 years old, skin types I-V. The evaluation was performed at baseline, 6 and 12 wee… Tue, 3 Apr 2018 04:00:00 GMT With New Team, Revance Readies for Launch of their Botox Competitor With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launch of for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar lines. Dustin Sjuts is the new Vice President of Strategy and Sales, Aesthetic and Therapeutic, Ben Putman is Vice President of Digital; and Marc Korenberg is the Senior Director of Commercial Operations. In addition, Erica Bazerkanian has been promoted to Vice President of M… Tue, 3 Apr 2018 04:00:00 GMT ASDSA Applauds USPSTF Endorsement of Behavioral Counseling to Prevent Skin Cancer The American Society for Dermatologic Surgery Association (ASDSA) applauds the recent US Preventive Service Task Force (USPSTF) endorsement of behavioral counseling to prevent skin cancer for individuals aged six months to 24 years with a fair skin type, including parents of young children. The ASDS/ASDSA encourages proactive methods that encourage sun-safe behaviors, knowing that changing behavior and reducing the number of skin cancer cases starts with patient education on sun safety and pr… Mon, 2 Apr 2018 04:00:00 GMT Escalier Biosciences Closes Financing, Focuses on Psoriasis Escalier Biosciences BV, a privately held biopharmaceutical company, this month closed $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventures and BioGeneration Ventures (BGV) completing the round. Escalier is developing both topical and oral RORγt drug candidates for psoriasis and expects to be in the clinic with its topical compound in mid 2018. "RORγt is a validated target for psoriasis and other autoimmune disorders and ou… Fri, 30 Mar 2018 04:00:00 GMT